Evidence map›Paper›PMID 27494825›Full record

ArticleBlood cancer journal2016

Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene.

A Hayashi, R Tanoshima, S-I Tsujimoto, M Yanagimachi, M Takeuchi, K Sasaki, J Ikeda, R Kajiwara, S Ito, H Takahashi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. JMML genomics and decisions.Hematology. American Society of Hematology. Education Program · 2018
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A HayashiDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
R TanoshimaDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
S-I TsujimotoDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
M YanagimachiDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
M TakeuchiDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
K SasakiDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
J IkedaDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
R KajiwaraDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
S ItoDepartment of Pediatrics, Yokohama City University, Yokohama, Japan.
H TakahashiDepartment of Pediatrics, Toho University School of Medicine, Tokyo, Japan.
Yokohama City University · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, NeoplasmAnaplastic Lymphoma KinaseChild, PreschoolCombined Modality TherapyCrizotinibFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteOncogene Proteins, FusionProtein Kinase InhibitorsPyrazolesPyridinesReceptor Protein-Tyrosine KinasesRemission InductionTransplantation, HomologousALK protein, humanAnaplastic Lymphoma KinaseCrizotinibOncogene Proteins, FusionProtein Kinase InhibitorsPyrazolesPyridinesRANBP2-ALK fusion protein, humanReceptor Protein-Tyrosine Kinases

Identifiers

PMID27494825
PMCPMC5022176
OpenAlexW2502200489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.